Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 PK and Safety Study of Sotatercept Weight-based vs Weight-banded Dosing in PAH
jRCT2061240077Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, single-blind trial of sotatercept in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Merck & Co. Primary endpoints: Steady-state average serum concentration of sotatercept and Adverse events and discontinuations due to adverse events. Started Jan 2025; status: completed.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on jRCT2061240077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240077.